Genmab — Oktober 2017
-
Copenhagen, Denmark; October 17, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 317 million in the third quarter of 2017. Net sales were USD 230 million in the U.S. and USD 87 million in the rest of the world. Genmab will receive royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to develop, manufacture and commercialize DARZALEX.
-
men J&J belønnes, så mon ikke stemningen vender igen https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=454235013&sourcecode=ddk
-
ingen chance for det JKY
-
Skyldes det dårlige salg ikke os sommerferien, færre klinikdage og orkaner?
-
Man kan kun konstatere at forummet her er for positive. De forsigtige analytikere ligger rigtigt med deres prognoser
-
altså vi kæmpe for at nå den nedre guideline for 2017
-
kæmper
-
Tror i forventer for meget.
-
@sukkeralf, med ingen vækst lander vi på 1134, du har ret
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind